Related Experiment Videos
Summary
The FDA approved the PD-1 inhibitor pembrolizumab for recurrent or metastatic cervical cancer. This approval, based on a phase II trial, showed an objective response rate of 14.3% in patients with PD-L1 expression.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Cervical cancer remains a significant global health challenge, particularly in recurrent or metastatic stages.
- Limited effective second-line treatment options exist for patients with advanced cervical cancer.
- Programmed cell death protein 1 (PD-1) inhibitors have emerged as a promising therapeutic strategy.